.png)
Dr. Jun Yang obtained his Ph.D. from Beijing Institute of Technology and completed postdoctoral research at Tsinghua University and New Jersey Institute of Technology. He has served as a senior formulation researcher at Mallinckrodt Pharmaceuticals in the U.S. and as the Director of R&D at Yichang Humanwell Pharmaceutical Co., Ltd.'s oral solid dosage plant. He is currently the President of the Pharmaceutical Research Institute at Humanwell Healthcare Group and the General Manager of Humanwell Pharmaceutical in the U.S.​
​
He has extensive experience in the research and management of innovative drugs, innovative formulations, and generic drugs, and is well-versed in the technical requirements for product development and regulatory strategy requirements in both China and the U.S. He has obtained multiple clinical and production approvals for innovative drugs, innovative formulations, and generic drug products from the China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). Additionally, he has published numerous academic papers and holds over ten patents and patent applications.​